• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Metastatic Brain Tumors - Pipeline Review, H2 2011 - Product Image

Metastatic Brain Tumors - Pipeline Review, H2 2011

  • ID: 1881604
  • August 2011
  • 65 pages
  • Global Markets Direct

Metastatic Brain Tumors - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Metastatic Brain Tumors - Pipeline Review, H2 2011', provides an overview of the Metastatic Brain Tumors therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Brain Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Brain Tumors. 'Metastatic Brain Tumors - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Brain Tumors.
- A review of the Metastatic Brain Tumors products under development READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metastatic Brain Tumors Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Brain Tumors
Metastatic Brain Tumors Therapeutics under Development by Companies
Metastatic Brain Tumors Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Metastatic Brain Tumors Therapeutics - Products under Development by Companies
Metastatic Brain Tumors Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Brain Tumors Therapeutics Development
Geron Corporation
Metastatic Brain Tumors - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
GRN1005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-alanosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Thiotepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Thiotepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EMD 121974 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
O6-Benzylguanine + Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dactinomycin + Filgrastim + Cisplatin + Cyclophosphamide + Cytarabine + Dexrazoxane + Doxorubicin + Etoposide + Leucovorin + Methotrexate + Temozolomide + Hydrocortisone + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carmustine + mercaptopurine + streptozocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lapatinib ditosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Laromustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + carboplatin + cisplatin + cyclophosphamide + etoposide + leucovorin calcium + methotrexate + temozolomide + thiotepa + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + carboplatin + cisplatin + cyclophosphamide + etoposide + leucovorin calcium + methotrexate + temozolomide + thiotepa + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Etoposide + Trofosfamid + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cisplatin + lomustine + vincristine sulfate + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erlotinib + sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gefitinib + temozolomide + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erlotinib + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Temsirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib Tosylate + Stereotactic Radiosurgery - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Brain Tumors Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Metastatic Brain Tumors, H2 2011
Products under Development for Metastatic Brain Tumors – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Geron Corporation, 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Metastatic Brain Tumors Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Metastatic Brain Tumors, H2 2011
Products under Development for Metastatic Brain Tumors – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos